title: Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
authors.forename: Kristel M
authors.initials: KM
authors.lastname: Crommentuyn
authors.forename: Alwin D
authors.initials: AD
authors.lastname: Huitema
authors.forename: Kees
authors.initials: K
authors.lastname: Brinkman
authors.forename: Marchina E
authors.initials: ME
authors.lastname: van der Ende
authors.forename: Frank
authors.initials: F
authors.lastname: de Wolf
authors.forename: Jos H
authors.initials: JH
authors.lastname: Beijnen
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000097:blood / Q000493:pharmacokinetics*; D016903:Drug Monitoring / Q000379:methods*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine